Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death

Pfizer, Press Release, NCT05011513, Dec 2021
Early treatmentRCT · 854 patients · multinational · Aug 2021 – Jul 2022
Paxlovid for COVID-19
Pfizer Press Release · December 2021 · NCT05011513
Outcome
Improvement
Relative Risk · 95% CI
00.511.52+
← Paxlovid
reduces risk
Paxlovid
increases risk →
Lower hospitalization with paxlovid
Not statistically significant · p = 0.051
EPIC-SR trial interim results, 428 patients treated with paxlovid (PF-07321332 + ritonavir) and 426 control patients, showing lower hospitalization with treatment. NCT05011513 (history).
OutcomeImprovementEffect · pTreatmentControl
risk of hospitalization 70.1% lower · RR 0.30 · p = 0.05 70.1% lowerRR 0.30p = 0.05 3 of 428 (0.7%) 10 of 426 (2.3%) treatment 3 of 428 (0.7%), control 10 of 426 (2.3%)NNT 61

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Pfizer et al., 14 Dec 2021, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, study period 25 August, 2021 - 25 July, 2022, trial NCT05011513 (history).